VITASORA HEALTH LIMITED — Call Transcript 2018

Nov 8, 2018

ASX ANNOUNCEMENT

9 November 2018

==> picture [162 x 67] intentionally omitted <==

SHAREHOLDER UPDATE | NOVEMBER 2018

Respiri Limited (ASX:RSH) is pleased to extend an invitation to shareholders to join a scheduled conference call featuring a debrief on the recent London Medical and Scientific Advisory Board and Study Planning Meeting with Professor Bruce Thompson, Head of Physiology Services, Alfred Hospital, President Elect, Thoracic Society ANZ and Chair of Respiri’s Australian Medical and Scientific Advisory Board.

CEO, Mario Gattino, stated “We know our shareholders are very keen to hear about how we plan to develop the scientific and clinical evidence that will support our product claims with the Medical Community. The meeting in London was a landmark event and hearing first hand from an expert with Professor Thompson’s credentials is a rare treat for a company like Respiri, hope you can join us.”

Mario will also be joined by Wani Wall, Chief Customer Experience and Communications Officer to provide an operational update focused on stated milestones to date and major deliverables towards the successful launch of the Wheezo asthma monitoring technology in first half of next year.

CONFERENCE CALL SCHEDULED Tuesday 13 November 2018 | 09:30am AEDT Telephone: 1800 123 296 Conference ID: 2797829

CONFERENCE SPEAKERS

==> picture [127 x 129] intentionally omitted <==

==> picture [126 x 130] intentionally omitted <==

==> picture [118 x 129] intentionally omitted <==

Mario Gattino, CEO & Director, Respiri Limited

Professor Bruce Thompson, Head of Physiology Services, Alfred Hospital

Wani Wall, Chief CX & Communications Officer, Respiri Limited

respiri.co

ABOUT RESPIRI LIMITED

Respiri’s mission is to help improve quality of life for millions of children and adults around the world and dramatically reduce hospital admissions and the economic burden of asthma. The Company offers sensors, mobile apps and analytics to support respiratory health management. Its world first technology detects wheeze, a typical symptom of asthma, COPD and respiratory disease to provide an objective measure of airway limitation. Respiri's innovative platform provides personalised feedback and education based on the user's data and enables the sharing of that data with caregivers and health care providers. Respiri Limited's operations are based in Melbourne, Australia.

FORWARD LOOKING STATEMENTS

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on Respiri’s current expectations, estimates and projections about the industry in which Respiri operates, and its beliefs and assumptions. Words such as "anticipates," "expects," "intends," "plans," "believes," "seeks,” "estimates,“ “guidance” and similar expressions are intended to identify forward looking statements and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those risks or uncertainties inherent in the process of developing technology and in the endeavour of building a business around such products and services. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors, some of which are beyond the control of Respiri, are difficult to predict and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. Respiri cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Respiri only as of the date of this release. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. Respiri will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

respiri.co